Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GenFleet Therapeutics (Shanghai) EBITDA Margin % Related Terms
GenFleet Therapeutics (Shanghai) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02595 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GenFleet Therapeutics (Shanghai) EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a EBITDA Margin % of -2,619.73% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. According to the industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #774 out of 942 companies in the Biotechnology industry, placing it in the top 82.2%.
Is GenFleet Therapeutics (Shanghai)'s EBITDA Margin % too high?
GenFleet Therapeutics (Shanghai)'s current EBITDA Margin % is -2,619.73%. Based on the distribution chart, GenFleet Therapeutics (Shanghai) ranks #774 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GenFleet Therapeutics (Shanghai) ranks #774 out of 942 companies for EBITDA Margin %. This places GenFleet Therapeutics (Shanghai) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current EBITDA Margin % is -2,619.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a current EBITDA Margin % of -2,619.73%. The current EBITDA Margin % is -2,619.73%. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HKSE:02595), the current EBITDA Margin % is -2,619.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
10GF Score
Get the complete analysis for HKSE:02595
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02595 has been successfully added to your 
